Nothing said here yet.
to join the conversation.
| Borges David J.VP, Finance & CAO | Sell | 10,000 | $209.5K | Wed, Sep 23 |
| Borges David J.VP, Finance & CAO | Sell | 10,000 | $209.5K | Tue, Sep 22 |
| Cancelmo Peter BVP, General Counsel | Sell | 25,000 | $463.5K | Mon, Aug 31 |
| Cancelmo Peter BVP, General Counsel | Sell | 25,000 | $466.1K | Fri, Aug 28 |
| HANISH ARNOLD CDirector | Sell | 5,000 | $95.1K | Thu, Aug 27 |
| HANISH ARNOLD CDirector | Sell | 5,000 | $94.4K | Thu, Aug 27 |
| HANISH ARNOLD CDirector | Sell | 5,000 | $92.6K | Wed, Aug 26 |
| Borges David J.VP, Finance & CAO | Sell | 906 | $17.3K | Mon, Aug 24 |
| Borges David J.VP, Finance & CAO | Sell | 10,000 | $189.5K | Fri, Aug 21 |
| Cable Thomas J.Director | Sell | 15,000 | $276.8K | Thu, Aug 20 |
| Borges David J.VP, Finance & CAO | Sell | 5,000 | $84.8K | Thu, Aug 13 |
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a negative opinion on Omeros’ marketing authorization application for narsoplimab, sold as Yartemlea in the United States, the company said on Friday.
Omeros Corporation (NASDAQ:OMER) shares declined 4% in Friday morning trading after the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) maintained its negative opinion on the company’s marketing authorisation…
Investing.com -- Shares of Omeros Corporation (NASDAQ: OMER) retreated 4% in Friday morning trading after the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) maintained a negative opinion on the marketing authorization…
European regulators rejected Omeros’ application for Narsoplimab, which is used to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy.
Natera’s Signatera test secured a key regulatory approval, while Cantor raised its sales expectations for Omeros’ lead drug, Yartemlea.
Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?